

**Amendments to the Claims**

Claim 11 has been amended without any intention of disclaiming equivalents thereof. New claim 29 has been added. The following list of claims replaces all prior versions and lists of claims in the application.

**What is claimed is:**

1. – 10. (Cancelled).
11. (Currently Amended) A sterile, liquid pharmaceutical composition for intranasal administration to a mammal comprising: an effective amount of midazolam or pharmaceutically acceptable salt thereof for inducing rapid sedation, anxiolysis, amnesia or anesthesia when administered intranasally to a mammal, from about 15 % to about 25 % by volume polyethylene glycol, and propylene glycol.
12. (Original) A pharmaceutical composition according to claim 11, wherein the polyethylene glycol comprises from about 15% to about 25% by volume and the propylene glycol constitutes from about 75% to about 85% by volume of the composition.
13. (Original) A pharmaceutical composition according to claim 11, wherein the composition contains a preservative.
14. (Original) A pharmaceutical composition according to claim 11, wherein the composition is preservative-free.
15. (Original) A pharmaceutical composition according to claim 11, wherein the composition contains an anesthetic agent.
16. (Original) A pharmaceutical composition according to claim 11, wherein the composition achieves a time to maximum plasma concentration ( $T_{max}$ ) within about 5 minutes to about 20 minutes after intranasal administration.

17. (Original) A pharmaceutical composition according to claim 11, wherein the composition achieves a time to maximum plasma concentration ( $T_{max}$ ) within about 5 minutes after intranasal administration.

18. (Original) A pharmaceutical composition according to claim 11, wherein the composition achieves a maximum plasma concentration ( $C_{max}$ ) of about 40 ng/mL from a 2.5 mg dose or about 80 ng/mL from a 5 mg dose after intranasal administration.

19. (Cancelled)

20. (Previously presented) A method of treating a mammal in need of rapid sedation, anxiolysis, amnesia, or induction of anesthesia comprising intranasally administering to the mammal the composition of claim 11, wherein the rapid sedation, anxiolysis, amnesia, or induction of anesthesia occurs within 5 minutes after intranasal administration.

21 - 26. (Cancelled)

27. (Previously presented) The composition of claim 11, wherein the polyethylene glycol is polyethylene glycol 400.

28. (Previously presented) The method of claim 20, wherein 5 mg of midazolam is administered to the mammal so as to provide rapid sedation, anxiolysis, or induction of anesthesia.

29. (New) The composition of claim 11, wherein the composition comprises no less than 25 mg/mL midazolam or a pharmaceutically acceptable salt thereof.